• Company
• K-similars compete for Canada's ₩31 tril market
• by Nov 25, 2022 06:05am

• Company
• Janssen Korea to reduce workforce...conducts VSP
• by Eo, Yun-Ho Nov 25, 2022 06:05am

• Opinion
• [Reporter's view] Godex benefit adequacy will be further di
• by Lee, Tak-Sun Nov 25, 2022 06:05am

• Policy
• SGLT2+DPP4 standards expanded, will it be over again?
• by Lee, Tak-Sun Nov 24, 2022 05:51am

• Company
• First ASMD treatment Xenpozyme to land in Korea
• by Eo, Yun-Ho Nov 24, 2022 05:51am

• Company
• Shaperon applies for a patent for biomarkers,
• by Lee, Seok-Jun Nov 24, 2022 05:50am

• Company
• Chong Kun Dang CKD-701, equivalent to Lucentis' original
• by Chon, Seung-Hyun Nov 24, 2022 05:50am

• Company
• SK Bio "hasn't manufactured SKYCovione after first batch"
• by Kim, Jin-Gu Nov 24, 2022 05:50am

• Policy
• COVID vaccine side effects proven by the Government
• by Kim, Jung-Ju Nov 24, 2022 05:50am

• Policy
• The government are in full swing discussing support
• by Lee, Jeong-Hwan Nov 24, 2022 05:50am